<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00973739</url>
  </required_header>
  <id_info>
    <org_study_id>09-0328</org_study_id>
    <nct_id>NCT00973739</nct_id>
  </id_info>
  <brief_title>Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors</brief_title>
  <official_title>Phase II Study of Lapatinib in Children and Adults With Neurofibromatosis Type 2(NF2) and NF2-related Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Lapatinib has any effect on tumors found in
      patients with Neurofibromatosis Type 2 (NF2). NF2 is a condition that mainly affects the skin
      and nervous system. It causes non-cancerous tumors (which are known as neuromas) to grow on
      the nerves around a person's body. Some signs of NF2 include a gradual loss of hearing and
      tumors growing on the skin, the brain and the spinal cord which can lead to complications.

      Lapatinib is an oral drug that is approved by Food and Drug Administration (FDA) for other
      types of tumors, it is not approved by the FDA for treatment of NF2 related tumors. The
      investigators know a lot about how well it is tolerated, but the investigators do not know if
      it is effective in treating your condition, therefore it is considered to be an
      investigational medication. This study will test whether Lapatinib may shrink tumors commonly
      found in patients with NF2 or stop them from growing. This will help us to decide if
      Lapatinib should be used to treat NF2 patients in future. Lapatinib is a drug that has been
      used for over 10 years to treat various forms of cancer. It has not been studied for the
      treatment of tumors in NF2 patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this trial, we propose to assess the objective response rates to Lapatinib in patients
      with NF2-related tumors. Lapatinib is a commercially available inhibitor of ErbB2 and EGF.
      Data suggests that abnormal signaling via EGFR and ErbB2 is a major contributor to tumor
      growth and progression in both sporadic and NF2-related VS and that inhibition of this
      signaling pathway can result in decreased tumor growth.

      Demonstrating that Lapatinib produces an objective response to reduce tumor volume or
      stabilize disease will provide additional treatment options for NF patients with multiple
      tumor growth. For patients with VS we expect to see ≥ 10 dB improvement in PTA and/or
      improvement in SDS, compared to the audiogram at initiation of treatment. Currently there are
      no available treatment options for NF2 patients with multiple tumors. Depending on tumor cell
      type, lapatinib has cytostatic or cytotoxic antitumor effects, and in a recent study
      assessing the biological effects of Lapatinib on the associated molecular pathways and tumor
      growth in patients with solid tumors, a correlation was seen between tumor response and
      pre-treatment levels of (phosphor)-ErbB2 and (phosphor)-ERK1/2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated Volumetric Progression Free Survival at 12 Months</measure>
    <time_frame>Every three months for one year</time_frame>
    <description>Measurements were taken every three months, up to one year. Estimated volumetric progression free survival (PFS) was measured from date of enrollment to date of volumetric progression. PFS was analyzed using the Kaplan-Meier method in terms of overall PFS (volumetric or hearing progression), volumetric progression, and hearing progression.
Point estimates for PFS with 95% confidence intervals (CIs) were calculated from Kaplan-Meier curves.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated Volumetric Progression Free Survival for Hearing at 12 Months</measure>
    <time_frame>Every three months for one year</time_frame>
    <description>Measurements were taken every three months, up to one year. Estimated volumetric progression free survival (PFS) was measured from date of enrollment to date of hearing progression. PFS was analyzed using the Kaplan-Meier method in terms of overall PFS (volumetric or hearing progression), volumetric progression, and hearing progression.
Point estimates for PFS with 95% confidence intervals (CIs) were calculated from Kaplan-Meier curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Experiencing Grades 1 or 2 Toxicities (CTCAE)</measure>
    <time_frame>Baseline through one year</time_frame>
    <description>Toxicity was assessed throughout the study, up to one year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Experiencing Grade 3 Toxicities (CTCAE)</measure>
    <time_frame>Baseline through one year</time_frame>
    <description>Toxicity was assessed throughout the study, up to one year.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Neurofibromatosis 2</condition>
  <condition>Vestibular Schwannoma</condition>
  <arm_group>
    <arm_group_label>Lapatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lapatinib PO dosed according to age:
Children/adolescents (less than 18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO twice daily
Adults (18 years of age or older): 1,500 mg PO once daily
Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.
Children/adolescents (&lt;18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily)
Adults (&gt;=18 years of age): 1,500 mg PO (6 tablets once daily)
Duration: Up to 12 months, depending on treatment response.</description>
    <arm_group_label>Lapatinib</arm_group_label>
    <other_name>Tykerb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be at least 4 years of age.

          2. Patients must meet diagnostic criteria for NF2 and at least one volumetrically
             measured NF2-related brain or spinal tumor with radiographic evidence of progression
             over the past 12 months, designated as the primary target OR volumetrically measurable
             VS with ipsilateral progressive hearing loss over the past 12 months, designated as
             the primary target tumor.

          3. Significant hearing loss criteria for enrollment.

          4. Karnofsky (PS) OR Lansky 50-100% (&gt;16 years of age)

          5. Absolute neutrophil count ≥ 1,000/mm3 g/dL

          6. Hemoglobin ≥ 8 g/dL

          7. Creatinine ≤ 1.5 times upper limit of normal (ULN) OR corrected glomerular filtration
             rate ≥ 70 ml/min

          8. Bilirubin ≤ 1.5 times ULN

          9. ALT ≤ 2.5 times ULN

         10. Fully recovered from acute toxic effects of any prior chemotherapy, biological
             modifiers or radiotherapy.

         11. Steroids are allowed for progressive symptoms but patient must be on a stable dose for
             at least 1 week prior to study entry.

         12. Any neurologic deficits must be stable for ≥ 1 week.

         13. Patients with the potential for pregnancy or impregnating their partner must agree to
             follow acceptable birth control methods to avoid conception. Women of childbearing
             potential must have a negative pregnancy test. The anti-proliferative activity of this
             experimental drug may be harmful to the developing fetus.

         14. Normal cardiac left ventricular ejection fraction (LVEF) by transthoracic
             echocardiogram.

         15. Able to provide written informed consent (or consent by parent/legal guardian for
             minors)

        Exclusion Criteria:

          1. Patients with serious concurrent infection or medical illness.

          2. Neurological deficits that are rapidly progressing.

          3. Patients who are pregnant or breast-feeding.

          4. Anti-tumor therapy within 4 weeks prior to enrollment.

          5. Radiation therapy within 2 months prior to enrollment.

          6. Prior therapy with agents targeting EGFR or ErbB2.

          7. Any surgery within 4 weeks prior to enrollment.

          8. Significant gastrointestinal disorder(s)

          9. Known cardiac disease

         10. Patients with a concurrent or prior malignancy are ineligible unless they are patients
             with curatively treated carcinoma-in-situ or basal cell carcinoma of the skin.
             Patients who have been free of disease (any prior malignancy) for more than five years
             are eligible for this study.

         11. Patients cannot have received cytochrome P450-inducing anticonvulsants (EIADs; e.g.,
             phenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine) or similar agents
             (e.g., rifampin) or P450-inhibiting agents (Ketoconazole, Itraconazole,
             Clarithromycin, Atazanavir, Indinavir, Nefazodone, Nelfinavir, Ritonavir, Saquinavir,
             Telithromycin, Voriconazole)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias A Karajannis, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <results_first_submitted>June 27, 2013</results_first_submitted>
  <results_first_submitted_qc>February 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 22, 2016</results_first_posted>
  <last_update_submitted>February 19, 2016</last_update_submitted>
  <last_update_submitted_qc>February 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NF-2</keyword>
  <keyword>NF-2 related tumors</keyword>
  <keyword>Schwannoma, Acoustic, Bilateral</keyword>
  <keyword>schwannomas</keyword>
  <keyword>Neurilemmoma of other cranial and peripheral nerves</keyword>
  <keyword>NF2 related benign intracranial tumors including</keyword>
  <keyword>NF2 related meningiomas</keyword>
  <keyword>NF2 related ependymomas</keyword>
  <keyword>NF2 related spinal neurofibromas</keyword>
  <keyword>NF2 related gliomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Neurilemmoma</mesh_term>
    <mesh_term>Neuroma, Acoustic</mesh_term>
    <mesh_term>Neurofibromatosis 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twenty-one patients were enrolled between October 2009 and March 2011 at New York University Medical Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lapatinib</title>
          <description>Lapatinib will be administered</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lapatinib</title>
          <description>Lapatinib will be administered</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Estimated Volumetric Progression Free Survival at 12 Months</title>
        <description>Measurements were taken every three months, up to one year. Estimated volumetric progression free survival (PFS) was measured from date of enrollment to date of volumetric progression. PFS was analyzed using the Kaplan–Meier method in terms of overall PFS (volumetric or hearing progression), volumetric progression, and hearing progression.
Point estimates for PFS with 95% confidence intervals (CIs) were calculated from Kaplan–Meier curves.</description>
        <time_frame>Every three months for one year</time_frame>
        <population>This analysis is based on the 17 evaluable patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib</title>
            <description>Lapatinib PO dosed according to age:
Children/adolescents (less than 18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO twice daily
Adults (18 years of age or older): 1,500 mg PO once daily
Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Volumetric Progression Free Survival at 12 Months</title>
          <description>Measurements were taken every three months, up to one year. Estimated volumetric progression free survival (PFS) was measured from date of enrollment to date of volumetric progression. PFS was analyzed using the Kaplan–Meier method in terms of overall PFS (volumetric or hearing progression), volumetric progression, and hearing progression.
Point estimates for PFS with 95% confidence intervals (CIs) were calculated from Kaplan–Meier curves.</description>
          <population>This analysis is based on the 17 evaluable patients.</population>
          <units>Liklihood of PFS at 12 months</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6" lower_limit="43.1" upper_limit="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Volumetric Progression Free Survival for Hearing at 12 Months</title>
        <description>Measurements were taken every three months, up to one year. Estimated volumetric progression free survival (PFS) was measured from date of enrollment to date of hearing progression. PFS was analyzed using the Kaplan–Meier method in terms of overall PFS (volumetric or hearing progression), volumetric progression, and hearing progression.
Point estimates for PFS with 95% confidence intervals (CIs) were calculated from Kaplan–Meier curves.</description>
        <time_frame>Every three months for one year</time_frame>
        <population>This analysis is based on the 17 evaluable patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib</title>
            <description>Lapatinib PO dosed according to age:
Children/adolescents (less than 18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO twice daily
Adults (18 years of age or older): 1,500 mg PO once daily
Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Volumetric Progression Free Survival for Hearing at 12 Months</title>
          <description>Measurements were taken every three months, up to one year. Estimated volumetric progression free survival (PFS) was measured from date of enrollment to date of hearing progression. PFS was analyzed using the Kaplan–Meier method in terms of overall PFS (volumetric or hearing progression), volumetric progression, and hearing progression.
Point estimates for PFS with 95% confidence intervals (CIs) were calculated from Kaplan–Meier curves.</description>
          <population>This analysis is based on the 17 evaluable patients.</population>
          <units>Liklihood of PFS at 12 months</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="43.3" upper_limit="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Experiencing Grades 1 or 2 Toxicities (CTCAE)</title>
        <description>Toxicity was assessed throughout the study, up to one year.</description>
        <time_frame>Baseline through one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib</title>
            <description>Lapatinib PO dosed according to age:
Children/adolescents (less than 18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO twice daily
Adults (18 years of age or older): 1,500 mg PO once daily
Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Experiencing Grades 1 or 2 Toxicities (CTCAE)</title>
          <description>Toxicity was assessed throughout the study, up to one year.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Experiencing Grade 3 Toxicities (CTCAE)</title>
        <description>Toxicity was assessed throughout the study, up to one year.</description>
        <time_frame>Baseline through one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lapatinib</title>
            <description>Lapatinib PO dosed according to age:
Children/adolescents (less than 18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO twice daily
Adults (18 years of age or older): 1,500 mg PO once daily
Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Experiencing Grade 3 Toxicities (CTCAE)</title>
          <description>Toxicity was assessed throughout the study, up to one year.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lapatinib</title>
          <description>Lapatinib will be administered</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion on echocardiogram</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Possible ectopic atrial bradycardia on EKG</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Premature supraventricular complexes on EKG</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hemorrhage - rectum (stools)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pain-Other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Increased ALT</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Increased AST</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Increased PTT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Decreased bicarbonate</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vasovagal syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Numbness L-S area</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin (Other)</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Stomatitis (oral cavity ulceration)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthias Karajannis, MD</name_or_title>
      <organization>New York University Langone Medical Center</organization>
      <phone>212-263-8400</phone>
      <email>matthias.karajannis@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

